Previous close | 990.80 |
Open | 984.70 |
Bid | 979.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 976.90 - 996.60 |
52-week range | 86.66 - 997.30 |
Volume | |
Avg. volume | 857,033 |
Market cap | 4.136T |
Beta (5Y monthly) | 0.21 |
PE ratio (TTM) | 66.28 |
EPS (TTM) | 14.86 |
Earnings date | 07 Aug 2024 |
Forward dividend & yield | 7.08 (1.04%) |
Ex-dividend date | 18 Aug 2023 |
1y target est | N/A |
Novo Nordisk (NVO) closed the most recent trading day at $142.50, moving +0.01% from the previous trading session.
A U.S. Senate health panel vote that was scheduled for its June 18 meeting, to decide whether to subpoena Novo to answer questions about U.S. prices for the blockbuster drugs, is no longer necessary and will be canceled, Senator Bernie Sanders, who chairs the committee, said. The subpoena would have required Novo President Doug Langa to testify at a July 10 hearing. Jorgensen will testify before the committee, and the hearing will be held in early September.
Eli Lilly unveiled its newest manufacturing facility in Concord, N.C., Friday. The facility will help alleviate GLP-1 shortages.